Composition: Per lyophilized ampoule:
Cytidine-5’-disodium monophosphate (CMP disodium salt)… 10 mg
- Uridine-5’-trisodium triphosphate (UTP trisodium salt)
- Uridine-5’-disodium diphosphate (UDP disodium salt)
- Uridine-5’-disodium monophosphate (UMP disodium salt)
on the whole ………………………………… 6 mg (equivalent to 2.660 mg of Uridine )
Excipient ……………………………………………………. q.s.
Per ampoule of solvent:
- Sodium chloride
- Aqueous vehicle, q.s. 2 ml.
- Treatment of neuropathies osteoarticular (sciatica, radiculitis, etc.), metabolic (diabetic, alcoholic polyneuritis, etc.), infectious (herpes zoster) origin, and a frigore.
- Neuralgia of the Facial, Trigeminal, Intercostal, Lumbago.
Posology and method of administration
Nucleo CMP Forte injections is administered by intramuscular route.
Adults: 1 injection daily by intramuscular route.
Children: 1 injection every 2 days by intramuscular route.
Not known. Unless that there exists an allergy to any of the components.
Special warnings and precautions for use
Introduce the whole content of the ampoule of solvent into the lyophilised ampoule, stir till completely dissolving the content of the latter. Inject by intramuscular route.
Interactions with other medicinal products and other forms of interaction
Pregnancy and lactation
Its use during pregnancy is not contraindicated. However, it is recommended that the dosage pattern is established by the physician.
Effects on the ability to drive and use machines
Have not been described, but if any adverse reaction attributable to the taking of the medicament appears, consult your physician or pharmacist.
Given the scarce toxicity of the preparation, poisoning is not foreseen, even by accident.
The pharmaceutical product Nucleo CMP forte is an association of 2 nucleotides: CMP and UTP. These nucleotides are present in the organism. For this reason it is difficult to make a test of classic pharmacokinetics, administering product and analyzing by means of usual analytical techniques the content in biological liquids, corresponding to the external contribution.
The unique form to do is administering it noticeable product radioactively that allows to externally differentiate the organic content from the contributed one.
The tests in humans with noticeable product are questioned ethically and legally. For this reason the tests of pharmacokinetics of Nucleo CMP forte have been realized with rats to which it has administered the 2 nucleotides to them marked with C-14 carbon. The maximum plasmatic concentration, as much from CMP as UTP, is obtained to the 20 minutes of its administration by oral route. The average life oscillates between 1.5 and 5 hours, in the phase of distribution alpha. Concerning the phase of distribution beta (elimination) the average life is of 8 hours. The UTP is eliminated mainly in the form of uridine. The CMP is eliminated in one first stage as cytosine and later also doses in the form of uridine despite rest of confers its participation in metabolic processes of the organisms.
The activity of Nucleo CMP forte is derived from the incorporation of its active principles in specific metabolic routes. Nucleo CMP forte contributes to the groups necessary phosphates for the metabolism of cerebrosides and the sphingomyelin and glycerophospholipids phosphatidic acids that constitute, main components of the myelin sheath, which confers to the product of trophic properties for the maturation and axonal regeneration of the nervous weave.
The experimental tests with animal to which a neuropathy takes place to them have shown that the administration of Nucleo CMP forte exerts a preventive action and curative. After the administration, it is verified that there is an increase of density of injured nervous fiber, as well as of its diameter, that is to say, increases to its consistency and thickness. This is translated in an activation of the mechanism of axonal regeneration and an increase of the speed of the axonal flow. Consequently, the inflammation is diminished, sensitivity is increased and the mobilization of affected zone improves.